Akebia Therapeutics is furthest along on an anemia pill that the company hopes will take the place of hormone injections. But there seems to be event more excitement in the business about a second treatment, meant to treat vascular leak. "These are multi-billion dollar markets," Chief Financial Officer Ian Howes stated.
Akebia's anemia drug, known only as AKB-6548, passed an important milestone recently when Akebia embarked on a Phase I clinical trial and the first steps toward bedside use. The pill manipulates genes to produce the erythropoietin (EPO) hormone that promotes the growth of red blood cells in bone marrow. It aspires to replace riskier injections and treat other anemia sufferers who can't handle current treatments.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The drug, AKB-6548, is an alternative to injections of the erythropoietin (EPO) hormone that promotes the growth of red blood cells in the kidney. Akebia's drug increases the natural production of EPO and, if successful through trials, the company thinks it can cut the costs of anemia treatments and expand the treatment to others who can't take EPO injections for health reasons.
Akebia called Dzao a pioneer in gene therapy for vascular disease. His research on the renin-angiotensin system (RAS), which regulates blood pressure, is credited with helping understand the role of the system in cardiovascular disease and develop RAS-based drugs.
The company stated it raised additional money to ensure the development of two of its drugs. Akebia plans later this year to start Phase I clinical trials on an oral medication designed to create new red blood cells in anemia patients. In addition, it wants to establish a human clinical proof of concept for a second drug that prevents vascular leak syndrome, in which blood components leak out of veins and into other systems -- a side effect of some cancer treatments.
Akebia stated it wants Ian A. W. Howes to help expand its pipeline of drugs. Along with anemia and vascular treatments, the company is also developing wound healing and cancer therapies.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.